Skip to contentR
Roivant Sciences Ltd.
R
ROIVRoivant Sciences Ltd. Q1 2024 · 10-Q
Revenue$7.99M$7.99M−63.1% vs Q1 2023 Net Income$95.30M$95.30MN/M vs Q1 2023 EPS Diluted$0.12$0.12N/M vs Q1 2023 Operating Income-$102,235,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Roivant Sciences Ltd. · CIK 1635088 · Engraved from SEC EDGAR
Free Cash Flowderived-$193,794,000N/M Margins · derivedOperating margin-1279.5%−1.3 pt vs Q1 2023
Net margin1192.7%+2542.2 pt vs Q1 2023
ended Jun 30, 2024 · filed Aug 9, 2024 · 40 d after period end